Elisabeth Stes

Molecular biologist morphed into science communicator. Interested in all things at the intersection of science and society.

[Elisabeth Stes @ElisabethStes]

Announcing our Targeted Protein Degradation symposium, bringing you the latest science on protein degraders.
📍@JanssenBelgium campus in Beerse on Sep 29.
👉🏽 Register here for this live event: https://t.co/YA1pJwvIDH

[Elisabeth Stes @ElisabethStes]

Have a Seat. Prachtige #diversityequityandinclusion campagne van @JanssenBelgium waarvan ik graag de 1ste aflevering deel. Aan het woord onze CEO Kris Sterkens & jong talent Lusine Harutyunyan. #HaveASeat. https://t.co/JwkXqeMlir

[Elisabeth Stes @ElisabethStes]

How single-cell hashing can reduce experimental cost: @JanssenBelgium combines forces with VIB to develop and evaluate emerging single-cell technologies. Congratulations to Jeroen Van Houdt & colleagues on the resulting Genome Biology publication!

[VIB @VIBLifeSciences]

🧫 Antibodies or lipids for single-cell multiplexing? @slava_mylka et al find different tissues require different approaches. Milestone paper by VIB @JanssenBelgium single-cell program including @steinaerts @CBD_VIB, @YvanSaeys @InflamResCenm @VIBTechWatch https://t.co/b0FUUFfYOB

[Elisabeth Stes @ElisabethStes]

The Dr. Paul Janssen Award honors researchers whose discoveries have made, or have the potential to make, significant contributions toward improving human health. 2022 nominations accepted thru 2/28 - nominate or share w/ your network! https://t.co/nyG9zGkbrs #DPJAward

[Elisabeth Stes @ElisabethStes]

@VIBLifeSciences managing director @JVanbiervliet was on TV this weekend! Watch him explain why Belgium is a leading country in biotech: https://t.co/vxpHr4Vohy @VRT

[Elisabeth Stes @ElisabethStes]

How do you keep up with your research field in life sciences? One excellent way is to follow @VIBConferences and attend one of their top conferences. It's a forum for academic & industry scientists to present their latest scientific achievements & technological solutions.

[VIB Training & Conferences @VIBTrainConf]

Welcome #twitterverse to VIB Conferences' own channel! Following this channel allows you to stay up to date with all the latest #VIB conference news, line-ups, deadlines and follow the different conferences via live tweeting. Find out more here: https://t.co/M67hNRbu8n #VIBConf

[Elisabeth Stes @ElisabethStes]

Does your research rely on recombinant protein production? Check out this new method to predict protein secretability by @NicoCallewaert, @mcboone, @compomics, @wmdeneve & colleagues @VIBLifeSciences, @ResearchUGent & @VUBrussel.
👉🏼Today in @NatureComms
https://t.co/FFoCrTiIEF

[Elisabeth Stes @ElisabethStes]

Forever a huge admirer of plant science at @VIBLifeSciences, as our research holds solutions to keep up food production while preserving the earth’s valuable ecosystems #whywecare #VIBforCOP26 @PSB_VIB

[Elisabeth Stes @ElisabethStes]

Follow #NHAD21 for live tweets from the @VIBLifeSciences conference about Alzheimer’s Disease research in @stadleuven

[Liesbeth Aerts @Liesbeth_Aerts]

Good morning everyone! @HoeckeLien, @sborrie and myself will be live tweeting from #NHAD21 today and tomorrow. Stay tuned for lots of exciting science!

[Elisabeth Stes @ElisabethStes]

Everyone knows someone touched by cancer. VIB scientists are continuously making progress in the prevention, detection & treatment of the disease #whywecare #dagtegenkanker

[BergersLab @BergersLab]

Today is "Dag tegen Kanker"/Day against Cancer. At our lab we are working hard every day to gain insights in cancer, and more specifically the tumor microenvironment. Thank you @komop_tgkanker for the support!
#whywecare #dagtegenkanker
@vib_ccb @Onco_KULeuven @VIBLifeSciences

[Elisabeth Stes @ElisabethStes]

One of the tricks #SARSCoV2 uses to outsmart our immune system involves removing a small protein modification, named ISG15. Read all about in 2 new papers of the @Impenslab at @VIBLifeSciences and @ResearchUGent #COVID19

[VIB @VIBLifeSciences]

🙌 Impressive work by @ImpensLab, @FabienThery1, @svennetti & @lradoshevich26. Their pioneering work on ISG15-mediated defenses vs. bacteria and viruses published in @NatureComms and @NatImmunol today!

👉 https://t.co/g9aVz7lH4y

@VIB_CMB @VIBLifeSciences @ugent @VIB_PRC

[Elisabeth Stes @ElisabethStes]

✨ Looking forward to the celebration this afternoon! We'll be tweeting live from the event in Brussels 👉Follow #25YearsVIB and join the conversation!

[VIB @VIBLifeSciences]

🎉 Today we celebrate our 25th anniversary! Discover our research, our story, and the origin of impact here 👉 https://t.co/PnUYR4rcs1

[Biotalys @biotalys]

As spin-off, Biotalys congratulates VIB with its 25th anniversary and celebrates the many scientific achievements in #biotech and #agtech made possible by this critical research institution 👏 https://t.co/gTT6FaOrUL #25YearsVIB

[Elisabeth Stes @ElisabethStes]

Congrats to @VIB_CMB on this impressive Science Transl. Med. paper on #COVID19 nanobodies 👌

[VIB @VIBLifeSciences]

🙌 Thrilled to see our #COVID19 research in @ScienceMagazine today! VIB @UGent scientists Xavier Saelens, @NicoCallewaert, Bert Schepens & co-workers developed COVID-19 antibody that is now tested in the clinic by VIB spin-off ExeVir! 👉 https://t.co/Dc8MAQq8Hf

[Elisabeth Stes @ElisabethStes]

🦩Hello VIB spin-off Flamingo Therapeutics 🦩
We are super proud of this spinoff based on the work of the @marine_lab at VIB and @KU_Leuven, with former colleague Floor Stam on board as COO. The startup develops cancer therapeutics based on RNA-targeted approaches.

[VIB @VIBLifeSciences]

✨VIB spin-off Flamingo Therapeutics could be a game changer in cancer treatment with RNA-targeted approach. Start-up, based on @lab_marine (VIB @KU_Leuven) & @pieter_mestdagh (@crighent @ugent) research, announced strategic alliance with @ionispharma

👉 https://t.co/fVbd2zsdUU

[Elisabeth Stes @ElisabethStes]

@VIB spin-off Protealis develops high yield & high-protein soybean for European farmers🌿CEO @Benjamin_Laga & team just announced a near doubling of capital thanks to massive intl. interest 🌟 Congratulations! https://t.co/RMzkdBypi8

[VIB @VIBLifeSciences]

✨VIB #spinoff is making big leaps! #ExeVir just announced the first patient dosed with #COVID19 antibody in phase 1b/2 clinical study.
Read more👉https://t.co/DMHVT8oXH8

#biotech #nanobodies #covid #clinicalstudy

[Elisabeth Stes @ElisabethStes]

https://t.co/DTOvDFL25u

[Elisabeth Stes @ElisabethStes]

We are so proud at VIB! Our spin-off ExeVir's #COVID19drug entered Phase I clinical trial. This antibody-based drug is developed by VIB-Ghent University labs of Nico Callewaert & Xavier Saelens https://t.co/by8o3KE2rb

[Elisabeth Stes @ElisabethStes]

https://t.co/ckhQAnXKuJ